Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT04516603
Other study ID # 2020-01626
Secondary ID
Status Withdrawn
Phase Phase 2
First received
Last updated
Start date October 1, 2020
Est. completion date December 31, 2021

Study information

Verified date October 2020
Source University of Basel
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Proof-of-concept study on the effects of 10 mg fampridine (oral administration) on working memory in healthy participants. The hypotheses is that fampridine improves working memory performance.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date December 31, 2021
Est. primary completion date December 31, 2021
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 30 Years
Eligibility Inclusion Criteria: - male or female - generally healthy - normotensive (BP between 90/60 mmHg and 140/90 mmHg) - BMI between 19 and 29,9 kg/m2 - aged between 18 and 30 years - fluent German-speaking - Informed consent as documented by signature Exclusion Criteria: - contraindications to the class of drugs under study, e.g. known hypersensitivity or allergy to 4-aminopyridine - use of potassium channel blockers within the last 3 months - concomitant treatment with OCT 2 inhibitors (e.g. cimetidine, propranolol) - acute or chronic psychiatric disorder (e.g. major depression, psychoses, somatoform disorder, suicidal tendency) - acute cerebrovascular condition - history of seizures - risk of lowered seizure threshold (due to e.g. sleep deprivation, withdrawal of alcohol after alcohol abuse) - renal impairment - history of malignant cancers - walking problems (e.g. due to dizziness) - other clinically significant concomitant disease states (e.g. hepatic dysfunction, cardiovascular disease, diabetes, asthma) - clinically significant laboratory or ECG abnormality that could be a safety issue in the study - known or suspected non-compliance - drug or alcohol abuse - inability to follow the procedures of the study, e.g. due to language or psychological problems of the participant - participation in another study with an investigational drug within the 30 days preceding and during the present study - prior participation (less than two years ago) in a study investigating working memory (notably the n-back task) - enrolment of the investigator, his/her family members, employees and other dependent persons - smoking (>3 cigarettes per day) - intake of psychoactive drugs (e.g. benzodiazepines, antidepressants, neuroleptics) - pregnancy or breast feeding

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Fampridine SR
Fampridine is an inhibitor of voltage-gated potassium (Kv) channels and is approved in Switzerland for treatment of gait problems in patients with Multiple Sclerosis (MS).
Placebo
no active component

Locations

Country Name City State
Switzerland University of Basel, Transfaculty Research Platform Basel BS

Sponsors (3)

Lead Sponsor Collaborator
Prof. Dominique de Quervain, MD Clinical Trial Unit, University Hospital Basel, Switzerland, University Hospital, Basel, Switzerland

Country where clinical trial is conducted

Switzerland, 

Outcome

Type Measure Description Time frame Safety issue
Primary Medium-load working memory performance Accuracy as assessed by a letter n-back task (Papassotiropoulos, Henke et al. 2011) with the levels 0-back and 2-back.
This test includes a 2-back task assessing working memory and a 0-back task ('x-target' task) measuring concentration. The 2-back task requires participants to respond to a letter repeat with one intervening letter (for example, S-m-s-g…). The 'x-target' task requires participants to respond to the occurrence of the letter 'x' in a sequence of letters (for example, N-l-X-g…). Accuracy (i.e. correct 2-back responses minus correct 0-back responses) will be calculated.
test day 1 and 2, each 4 hours after intake of study medication to assess differences between the Verum and Placebo condition
Secondary Reaction time Reaction time for correct 2-back responses minus correct 0-back responses. test day 1 and 2 each 4 hours after intake of study medication to assess differences between the Verum and Placebo condition
Secondary N-back with a 3-back condition N-back with a 3-back condition, which is more demanding than the 2-back condition. Accuracy (3-back minus 0-back) will be calculated. test day 1 and 2 each 4 hours after intake of study medication to assess differences between the Verum and Placebo condition
Secondary Symbol Digit Modalities Test, SDMT Symbol Digit Modalities Test, SDMT (Smith 2013, 13th edition), a processing speed test. The test consists of the presentation of a series of 9 symbols, each of them is paired with a single digit, labeled 1-9, in a key at the top of a sheet. The remainder of the page has a pseudorandomized sequence of the symbols and the participant must respond with the digit associated with each of these as quickly as possible. The score is the number of correct answers in 90 seconds. The administration of SDMT will be preceded by a learning sequence at both timepoints. A parallel version will be used for the second test day. test day 1 and 2 each 4 hours after intake of study medication to assess differences between the Verum and Placebo condition
Secondary Bochumer Matrizentest (BOMAT - advanced -short) Bochumer Matrizentest (BOMAT - advanced -short; Hossiep/Turck/Hasella, 2001, 1st edition), matrix reasoning. The BOMAT will be administered to measure fluid intelligence (Gf) consisting of 29 items. A time-limited version will be used according to Jaeggi (Jaeggi 2010). The total score is calculated by summing the correct solutions, ranging between 0 to 29. A parallel version will be used for the second test day. test day 1 and 2 each 4 hours after intake of study medication to assess differences between the Verum and Placebo condition
Secondary Digit Span Task Digit span task, a subtest of the "Wechsler Intelligenztest für Erwachsene" (WIE;von Aster 2006). Total scores for digit span forward and backward will be calculated as described in the manual of the WIE. A parallel version will be used for the second test day. test day 1 and 2 each 4 hours after intake of study medication to assess differences between the Verum and Placebo condition
See also
  Status Clinical Trial Phase
Recruiting NCT05399381 - Traveling-wave Transcranial Electric Stimulation N/A
Completed NCT05162729 - Working Memory and Social-emotional Training for Preschoolers at Risk of ADHD N/A
Recruiting NCT03666416 - Acute Effects of Exercise in College Students With ADHD N/A
Recruiting NCT05679882 - Effects of Natural Sounds on Attention Restoration Outdoors N/A
Recruiting NCT02823639 - Efficacy and Mechanisms of Transcranial Direct Current Stimulation (tDCS) - Effects on Working Memory in Schizophrenia N/A
Recruiting NCT03012269 - The Neural Substrates for Working Memory Training Phase 2/Phase 3
Completed NCT04328545 - Transcranial Direct Current Stimulation Effect on Pain Threshold and Working Memory: Impact of Age and Protocol Type N/A
Completed NCT04652557 - Influence of Fampridine on Working Memory in Healthy Young Subjects Phase 2
Recruiting NCT04680481 - Non-Invasive Brain Stimulation to Control Large-Scale Brain Networks N/A
Not yet recruiting NCT05923606 - Modulation of Brain Oscillations Underlying Working Memory N/A
Completed NCT04608370 - Transcranial Photobiomodulation Intervention for Healthy Older Adults N/A
Active, not recruiting NCT03147937 - Cognitive Changes After Major Joint Replacement - Full Trial (Cognigram 2)
Recruiting NCT05683587 - Effect of Ballet Course on Lower Limb Strength, Balance, Working Memory and the Compliance and Satisfaction N/A
Recruiting NCT03148678 - Scrutinizing and Promoting Mindfulness Via New Technologies N/A
Completed NCT04783740 - Validity and Reliability of Turkish Version of The Working Memory Questionnaire
Terminated NCT05736458 - Network Control TMS fMRI N/A
Terminated NCT04760054 - Effects of a Complex, Partnered Martial Arts-based Intervention on Cognitive Function N/A
Active, not recruiting NCT05274477 - Influence of Fampridine on Working Memory in Individuals With Post COVID-19 Condition With Subjective Cognitive Impairment N/A
Not yet recruiting NCT06469333 - Theories of Working Memory and Consolidation/RECOnsolidation in the Process of Resorption of Post-traumatic Symptoms. N/A
Completed NCT02964221 - Cognitive Changes After Major Joint Replacement N/A